PBIT is a potent, cell-permeable inhibitor of Jumonji histone demethylase (JHDM). Innhibits JARID1B (also known as KDM5B or PLU1) with an IC₅₀ of about 3 μm in vitro.

Parthenolide is a sesquiterpene lactone from the plant feverfew (T. parthenium).

Palovarotene (R-667, RO-3300074) is a selective retinoic acid receptor gamma(RAR-γ) agonist for the treatment of emphysema.

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

PAC-1 is a potent procaspase-3 activator with EC50 of 0.22 μM and the first small molecule known to directly activate procaspase-3 to caspase-3.

p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC50 of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay.

PF-1355 is a potent, selective, orally active Myeloperoxidase (MPO) inhibitor with EC50 of 1.47 uM.

MYCi975, also known as NUCC-0200975, is a potent and selective MYC Inhibitor. MYCi975 disrupts MYC/MAX interaction, promotes MYC T58 phosphorylation and MYC degradation, and impairs MYC driven gene expression.

Nicotinamide Mononucleotide, also known as ("NMN" and "β-NMN") is a nucleotide derived from ribose and nicotinamide Like nicotinamide riboside, NMN is a derivative of niacin, and humans have enzymes that can use NMN to generate nicotinamide adenine dinuc

NLX-101（F-15599） is a novel compound that activates serotonin 5-HT1A receptors with exceptional selectivity, having over 1000-fold higher affinity for this target over other receptors.

P22077 is a potent inhibitor of ubiquitin-specific protease (USP) 7 (EC50=8.6 uM), P22077 also inhibits the closely related deubiquitinase (DUB) USP47.

P005672 is a phase II drug for antibacterial/anti-inflammatory acne treatment.

P005091(P5091) is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM.

OTX008 is a selective inhibitor of galectin-1.

Omecamtivmecarbil (CK-1827452) is a specific cardiac myosinactivator and a clinical drug for left ventricular systolic heart failure.

O304 is a novel AMPK activator.

NVS-PAK1-1 potently inhibits autophosphorylation of PAK1 (S144) at 0.25 µM in the Su86.86 cell line and MEK S289 phosphorylation with an IC50 = 0.21 in Su86.86 cells in which PAK2 is downregulated.

NVP-CGM097 (CGM-097) is a potent and selective MDM2 inhibitor.

NUC-7738 is a phosphoramidate transformation of cordycepin (3’-deoxyadenosine; 3’-dA), a derivative of adenosine that was first isolated from Cordyceps sinensis.

NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

NSI-189 is a nootropic and neurogenic research chemical derived from nicotinamide and pyrazine.

NSC781406 is a highly potent PI3K and mTOR inhibitor with an IC50 of 2 nM for PI3Kα.

NSC617145 is a Werner syndrome helicase (WRN) helicase inhibitor (IC50 = 250 nM).

NSC348884 is a nucleolar phosphoprotein that displays several biological activities in ribosome biogenesis, cell proliferation, cytoplasmic/nuclear shuttle transportation, nucleic acid binding, ribonucleic cleavage, and centrosome duplication.

NS 9283 is a positive allosteric modulator of α4β2 receptor; increases the potency of Ach-evoked currents ~60 fold without effecting the maximum efficacy (HEK293-hα4β2 cells).

NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.

Nolatrexed (AG-337), inhibits purified recombinant human thymidylate synthase (TS) with a Ki of 11 nM, and displays non-competitive inhibition kinetics. It was further shown to inhibit cell growth in a panel of cell lines of murine and human origin, displ

NMS-873 is a potent, selective allosteric VCP/p97 inhibitor with IC50 value of 20 nM (Wild Type, 1 mM ATP).

NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.

NKP-1339 is the first-in-class ruthenium-based anticancer drug in clinical development against solid cancer and has recently been studied successfully in a phase I clinical trial.